Genomic Vision: New Strategic Development Area
23 Mars 2016 - 7:00AM
Business Wire
- Maximization of molecular combing’s
potential: targeting of the major and accessible Life Sciences
Research Tools (LSRT) market
- Opportunity to generate additional
revenue
- Synergies between the LSRT and in vitro
diagnostics (IVD) markets
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a
molecular diagnostics company specializing in the development of
diagnostic tests for genetic diseases and cancers based on
molecular combing technology, today presents a new strategic
development area.
Maximization of molecular combing’s potential on the Life
Sciences Research Tools (LSRT) market
Genomic Vision’s initiative naturally arises from the strength
of molecular combing technology, which enjoys a longstanding
excellent reputation in academic circles and major laboratories.
Since its first scientific publications, this innovative combing
technology has rapidly spread. Today, it is used by hundreds of
laboratories around the world in DNA replication research, but only
in an experimental and entirely manual version.
Aaron Bensimon, Co-founder and Chairman of Genomic
Vision, comments: “Thanks to the latest developments and
considerable improvements undertaken by Genomic Vision in recent
years on its combing platform, we are able to provide large
laboratories with technological breakthroughs that are essential
for their productivity and the quality of their research. The Life
Sciences Research Tools (LSRT) market, now represents an amazing
growth reservoir that we wish to target, in addition to clinical
diagnostics, thanks to a specific offer based on the automated
combing platform that we have perfected for diagnostics. A
comprehensive tools and consumables offer will enable us to meet,
in a simpler way, the requirements of these new clients who are
seeking standardized and automated solutions, notably in the key
DNA Replication research sector, where it has the potential to
become a gold standard. Since we’re enjoying a strong partnership
culture thanks to our extensive experience with Quest Diagnostics,
we also wish to accelerate our development through strategic
collaboration agreements with key players on this market that will
contribute to enhancing our product portfolio in new therapeutic
areas.”
An opportunity to generate additional revenue with a specific
LSRT offer
Simultaneously to its development on the in vitro diagnostics
market, Genomic Vision wants to boost its presence on the readily
accessible Life Sciences Research Tools market. This segment, with
a sales potential estimated to be worth 700 million dollars1,
represents a new value-creation territory with short-, medium- and
long-term revenue prospects.
The Company intends to take advantage of its technology’s
substantial historical foothold on this market segment by providing
research laboratories within biotechnology companies, large
pharmaceutical companies and major universities with turnkey
solutions enabling them to make full use of molecular combing’s
potential in the analysis of large genomic regions (Genomic Morse
Code (GMC) “on demand”), in DNA replication and in Gene editing
quality control and optimization tools (gene therapy):
- GMC on demand: Genomic Vision’s
proprietary technology enables genetic anomalies to be detected by
targeting genes or specific sequences in the patient’s genome by
tagging genetic biomarkers, thus providing clients with an accurate
visualization of regions of interest. An example of the deployment
of GMC on demand is the recent partnership between Genomic Vision
and the Imagine Institute in Paris.
- DNA replication: observable
during cell division, this process allows phenomena such as the
abnormal proliferation of cells in cancers to be studied. Today,
academic research laboratories and pharmaceutical companies are
looking for effective technologies to accurately interpret the
replication dynamics. Molecular combing makes it possible to
analyze the replication process with high-definition images while
providing detailed information about its dynamics.
- Gene editing quality control and
optimization tools: the aim of gene editing is to repair human
genomes that are carriers of mutations responsible for illnesses or
to improve the genome, for example in the case of gene therapies
with the well-publicized Crispr-Cas9 method. Molecular combing
offers substantial added value in the control and optimization of
these edited genes.
Synergies between the LSRT and IVD markets
With the experience gained from its strategic collaboration with
Quest Diagnostics, the American group that is the global leader in
laboratory diagnostic services, Genomic Vision also intends to
develop its partnership policy on the LSRT market. In 2015, the
Company already installed its combing platform at the Imagine
Institute, Europe’s largest genetic research and care cluster.
These types of partnerships will make it possible to study how
structural DNA variations are implicated in new pathologies and
will contribute to enhancing Genomic Vision’s genetic test
portfolio for the IVD market.
Continuation of the development of the BRCA, HPV, SMA and
HNPCC tests
The Company will continue to develop all its portfolio of IVD
tests:
Next financial publication
- Revenue for the 1st quarter of 2016, on
Tuesday May 10, 2016* (before market)* indicative date that may be
amended
ABOUT GENOMIC VISION
Founded in 2004, Genomic Vision is a molecular diagnostics
company that specializes in the development of diagnostic tests for
genetic diseases and cancers based on molecular combing. Using this
innovative technology that allows the direct visualization of
individual DNA molecules, Genomic Vision detects quantitative and
qualitative variations in the genome that are at the origin of
numerous serious pathologies. The Company is developing a solid
portfolio of tests that initially target breast and colon cancers.
Since 2013, the Company has marketed the CombHelix FSHD test for
identifying facioscapulohumeral dystrophy (FSHD), a myopathy that
is difficult to detect. It is marketed in the United States through
a strategic alliance with Quest Diagnostics, the American leader in
diagnostic laboratory tests, and in France directly by the Company.
Genomic Vision has been listed on Compartment C of Euronext Paris
since April 2014.
ABOUT MOLECULAR COMBING
DNA molecular combing technology significantly improves the
structural and functional analysis of DNA molecules. DNA fibers are
stretched over glass slides, as if "combed", and uniformly aligned
over the entire surface. It is then possible to identify genetic
anomalies by locating specific genes or sequences in the patient's
genome using genetic markers, a technique developed by Genomic
Vision and patented under the name Genomic Morse Code. This
exploration of the entire genome at high resolution via a simple
analysis enables the direct visualization of genetic anomalies that
are undetectable by other technologies.
For further information, please go to: www.genomicvision.com
Member of CAC® Mid & Small, CAC® All-Tradable
and EnterNext© PEA-PME 150 indexes
1 For US & 3 EU (FR, UK, DE) markets; Source: Company
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160322006607/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorKalimaRelations
PresseEstelle Reine-Adélaïde, +33 6 17 72 74 73Florence Calba, +33
1 44 90 82 54era@kalima-rp.frorLHAInvestor Relations USAnne
Marie Fields,
212-838-3777SVPafields@lhai.comorNewCapInvestor Relations /
Strategic CommunicationsDušan Orešanský / Emmanuel Huynh, +33 1 44
71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Goldfield (AMEX:GV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024